Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)
Authors:
- Christopher J. BurnsCBChristopher J. Burns
- David G. BourkeDBDavid G. Bourke
- Susan A. CharmanSCSusan A. Charman
- Emmanuelle FantinoEFEmmanuelle Fantino
- 1 October 2009
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (20) , 5887-5892
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patientsLeukemia, 2009
- JAKandMPLmutations in myeloid malignanciesLeukemia & Lymphoma, 2008
- JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trialsLeukemia, 2007
- CP-690550Drugs of the Future, 2007
- The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitorBlood, 2006
- Expedient Parallel Synthesis of 2-Amino-4-heteroarylpyrimidinesOrganic Letters, 2005
- Series Introduction: JAK-STAT signaling in human diseaseJournal of Clinical Investigation, 2002
- Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1Advanced Drug Delivery Reviews, 2001
- Janus kinases: components of multiple signaling pathwaysOncogene, 2000
- Palladium-Catalyzed Cross-Coupling Reactions of Organoboron CompoundsChemical Reviews, 1995